Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences SBC expense by award type — Stock Options
SBC expense by award type — Stock Options ($M) ($M)
Gilead Sciences SBC expense by award type — Stock Options: $30M in FY2025, unchanged from a year earlier.
Latest, FY2025
30
Period ended Dec 31, 2025
Change on a year earlier
0.0%
30 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-K Note 13 Stock-Based Compensation.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SBC expense by award type — Stock Options ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30 | 0.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 30 | 0.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 30 | +7.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 28 | -3.4% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 29 | -34.1% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 44 | – | Form 10-K (filed 2023-02-22) ↗ |
Cite this data
StockData. (2026). Gilead Sciences SBC expense by award type — Stock Options ($M), annual FY2020–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/sbc-opt-exp
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.